Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report) Senior Officer Adrian J. Haigh sold 22,223 shares of the stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of C$9.32, for a total transaction of C$207,029.47.
Adrian J. Haigh also recently made the following trade(s):
- On Monday, April 15th, Adrian J. Haigh bought 22,222 shares of Fennec Pharmaceuticals stock. The stock was purchased at an average cost of C$2.31 per share, with a total value of C$51,332.82.
Fennec Pharmaceuticals Price Performance
FRX traded down C$0.02 during trading on Tuesday, reaching C$12.80. 800 shares of the company traded hands, compared to its average volume of 726. The company has a debt-to-equity ratio of 881.09, a quick ratio of 10.17 and a current ratio of 3.29. Fennec Pharmaceuticals Inc. has a 12-month low of C$9.27 and a 12-month high of C$15.43. The firm has a fifty day simple moving average of C$13.51 and a 200 day simple moving average of C$12.72. The company has a market cap of C$346.11 million, a P/E ratio of -12.55 and a beta of 0.35.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Further Reading
- Five stocks we like better than Fennec Pharmaceuticals
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Charles Schwab Fortifies its Uptrend on EPS Beat
- How to Buy Cheap Stocks Step by Step
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Following Congress Stock Trades
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.